Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Lung cancer: actionable targets

Samreen Ahmed • 31 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib
ALTA-1L

Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses actionable target in lung cancer, drawing on data from the ALTA-1L study (NCT02737501) at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Samreen Ahmed

3:29
Novel strategies to treating brain metastases in lung cancer
Samreen Ahmed • 27 Mar 2023
0:54
Early lung cancer at ELCC 2023
Samreen Ahmed • 27 Mar 2023
0:55
Management of brain metastases associated with lung cancer
Samreen Ahmed • 27 Mar 2023
3:06
Highlights from the BTOG 2023 therapeutics symposium
Samreen Ahmed • 26 Apr 2023

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals